Sjögren综合征（SS）是一种免疫介导的炎症性疾病，以干燥综合征，肌骨疼痛和疲劳为特征。常见额外腺外症状，明显增加了淋巴瘤发生的风险。SS与症状负担导致的高健康经济负担相关联。目前，没有经过批准的疾病修饰治疗，管理范围基于经验性证据。对于SS病因的理解进展已经导致了一个在发展中的更加针对性的治疗组合。本综述总结了在SS中的目标生物治疗的关键发展，包括新出现的目标。同时，本文还着重强调了治疗发展中的挑战，如疾病的异质性和定义适当的疾病评估工具以评估治疗效果。SS早期的试验未能满足其主要结果，部分原因可能是由于使用不当或不敏感的研究终点。最近针对B细胞，B-T细胞共刺激和IFN信号的试验显示了有希望的结果。开发包括患者报告结果和客观疾病措施的组合终点可能提供更全面的疾病评估方法。这些新工具对于有益于患者的治疗发展的影响仍有待完全评估。

Sjögren's syndrome (SS) is an immune-mediated inflammatory condition characterized by sicca syndrome, musculoskeletal pain, and fatigue. Extra-glandular manifestations are common and there is a markedly increased risk of lymphoma development. SS is associated with high health-economic burden driven largely by the symptom burden on patients. Currently, there is no approved disease-modifying treatment and management is based on empirical evidence. Progress in the understanding of SS pathogenesis has led to an expanding portfolio of more targeted therapies under development.This review summarizes the key development in targeted biological therapies in SS including emerging targets. It also highlights the challenges in therapeutic development in SS such as disease heterogeneity and defining appropriate disease assessment tools to evaluate therapeutic efficacy.Early trials in SS failed to meet their primary outcomes which may in part due to the use of inappropriate or insensitive study endpoints. Recent trials targeting B-cells, B-T cell co-stimulation and IFN signaling have shown promising results. Development of composite endpoints including patient reported outcomes and objective disease measure may provide a more holistic approach to disease assessment. The impact of these new tools on therapeutic development that benefit patients remains to be fully evaluated.